Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Importance Tenecteplase is being evaluated as an alternative thrombolytic agent for the
treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In …

Within the last year, four randomised-controlled clinical trials (RCTs) have been published
comparing intravenous thrombolysis (IVT) with tenecteplase and alteplase in acute …

Importance Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke
thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of …

Background Neurointerventionists lack guidelines for the use of antithrombotic therapies in
their clinical practice; consequently, there is likely to be significant heterogeneity in …

Background: Intracranial occlusion site, contrast permeability, and clot burden are thrombus
characteristics that influence alteplase-associated reperfusion. In this study, we assessed …

Importance It is unknown whether intravenous thrombolysis using tenecteplase is
noninferior or preferable compared with alteplase for patients with acute ischemic stroke …

Purpose of review Alteplase has been the thrombolytic of choice for acute ischaemic stroke
for more than two decades. A thrombolytic which is easier to administer and with improved …

Background: Prior systematic reviews have compared the efficacy of intravenous
tenecteplase and alteplase in acute ischemic stroke, assigning their relative complications …

Background The performance of intravenous tenecteplase in patients who had an acute
ischaemic stroke with large/medium vessel occlusion or severe stenosis in an extended time …